Instrument Inactif

Communiqués ImmunoGen, Inc.

Actions

IMGN

US45253H1014

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AbbVie Completes Acquisition of ImmunoGen	12/02	PR
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/02	BU
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/01	AQ
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/01	BU
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLY	27/12	PR
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	10/12	BU
FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer	06/12	AQ
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer	05/12	BU
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN	05/12	BU
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/12	AQ
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/12	BU
Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio	30/11	AQ
Shareholder Alert: Ademi LLP investigates whether ImmunoGen, Inc. has obtained a Fair Price in its transaction with AbbVie	30/11	PR
IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders	30/11	BU
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio	30/11	PR
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference	02/11	BU
ImmunoGen: Q3 Earnings Snapshot	02/11	AQ
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results	02/11	BU
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/11	BU
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer	30/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ImmunoGen, Inc.

Actions

IMGN

US45253H1014

Communiqués

Filtres